Vascular Solutions (Nasdaq: VASC ) is expected to report Q4 earnings on Feb. 5. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Vascular Solutions's revenues will expand 15.9% and EPS will grow 21.4%.
The average estimate for revenue is $25.6 million. On the bottom line, the average EPS estimate is $0.17.
Last quarter, Vascular Solutions booked revenue of $24.6 million. GAAP reported sales were 1.0% higher than the prior-year quarter's $24.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $0.16. GAAP EPS of $0.16 for Q3 were 27% lower than the prior-year quarter's $0.22 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 66.7%, 260 basis points worse than the prior-year quarter. Operating margin was 16.9%, 540 basis points worse than the prior-year quarter. Net margin was 10.4%, 490 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $98.7 million. The average EPS estimate is $0.59.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 95 members out of 106 rating the stock outperform, and 11 members rating it underperform. Among 26 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 22 give Vascular Solutions a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Vascular Solutions is outperform, with an average price target of $16.15.
Is Vascular Solutions the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Vascular Solutions to My Watchlist.